Search research articles
Contact Us
Filters
Showing results (11-20 of 46) with videos related to
Page
of 5
Sort By:
European Journal of Cancer (Oxford, England : 1990)
|
August 5, 2025
Shallow whole-genome sequencing of circulating tumour DNA predicts clinical outcomes to systemic therapy in advanced hepatocellular carcinoma
Venkata Ramana Mallela, Sultan N Alharbi, Mathew Vithayathil, et al.
JAACAP Open
|
June 16, 2025
Safety and Tolerability of Brexpiprazole in Adolescents With Schizophrenia: A Long-Term, Open-Label Study
Sarah D Atkinson, Alpesh Shah, Maria Victoria Burgess, et al.
Future Oncology (London, England)
|
September 16, 2024
Safety and efficacy of itacitinib, a selective JAK1 inhibitor, in advanced hepatocellular cancer: Phase 1b trial (JAKAL)
Alessandro Troiani, Maria Martinez, Caroline Ward, et al.
Canadian Journal of Psychiatry. Revue Canadienne De Psychiatrie
|
March 1, 2024
Adjunctive Brexpiprazole for Patient Life Engagement in Major Depressive Disorder: A Canadian, Phase 4, Open-Label, Interventional Study: Brexpiprazole d'appoint pour l'engagement dans la vie des patients souffrant de trouble dépressif majeur: une étude interventionnelle canadienne ouverte de phase 4
François Therrien, Caroline Ward, Pratap Chokka, et al.
Journal of Clinical Pharmacology
|
July 18, 2023
Population Pharmacokinetic Analysis of Brexpiprazole to Support its Indication and Dose Selection in Adolescents With Schizophrenia
Yanlin Wang, Xiaofeng Wang, Frank Larsen, et al.
BMC Cancer
|
July 20, 2022
ArTisaN trial protocol: a single Centre, open-label, phase II trial of the safety and efficacy of TheraSphere selective internal radiation therapy (SIRT) in the treatment of inoperable metastatic (liver) neuroendocrine neoplasia (NENs)
Rohini Sharma, Susanna Slater, Joanne Evans, et al.
Journal of Clinical Psychopharmacology
|
July 2, 2025
52-Week Open-Label Safety and Tolerability Study of Centanafadine Sustained Release in Adults With Attention-Deficit/Hyperactivity Disorder
Gregory W Mattingly, Osman Turkoglu, Denise Chang, et al.
Current Medical Research and Opinion
|
June 9, 2026
Benefits and safety of brexpiprazole in adolescents living with schizophrenia: a plain language summary
Caroline Ward, Milica Pejović Milovančević, Nanco Hefting, et al.
Journal of Clinical Psychopharmacology
|
December 30, 2025
Effects of Adjunctive Brexpiprazole in Major Depressive Disorder Analyzed by Baseline Anxiety Level: Post Hoc Analysis of a Phase 4 Study
François Therrien, Caroline Ward, Zhen Zhang, et al.
Journal of Child and Adolescent Psychopharmacology
|
February 19, 2025
Safety and Efficacy of Brexpiprazole in the Treatment of Irritability Associated with Autism Spectrum Disorder: An 8-Week, Phase 3, Randomized, Double-Blind, Placebo-Controlled Trial and 26-Week Open-Label Extension in Children and Adolescents
Caroline Ward, Ann Childress, Krista Martinko, et al.
Page
of 5
Search research articles
Search
Showing results (11-20 of 46) with videos related to
Sort By:
Page
of 5
European Journal of Cancer (Oxford, England : 1990)
|
August 5, 2025
Shallow whole-genome sequencing of circulating tumour DNA predicts clinical outcomes to systemic therapy in advanced hepatocellular carcinoma
Venkata Ramana Mallela, Sultan N Alharbi, Mathew Vithayathil, et al.
JAACAP Open
|
June 16, 2025
Safety and Tolerability of Brexpiprazole in Adolescents With Schizophrenia: A Long-Term, Open-Label Study
Sarah D Atkinson, Alpesh Shah, Maria Victoria Burgess, et al.
Future Oncology (London, England)
|
September 16, 2024
Safety and efficacy of itacitinib, a selective JAK1 inhibitor, in advanced hepatocellular cancer: Phase 1b trial (JAKAL)
Alessandro Troiani, Maria Martinez, Caroline Ward, et al.
Canadian Journal of Psychiatry. Revue Canadienne De Psychiatrie
|
March 1, 2024
Adjunctive Brexpiprazole for Patient Life Engagement in Major Depressive Disorder: A Canadian, Phase 4, Open-Label, Interventional Study: Brexpiprazole d'appoint pour l'engagement dans la vie des patients souffrant de trouble dépressif majeur: une étude interventionnelle canadienne ouverte de phase 4
François Therrien, Caroline Ward, Pratap Chokka, et al.
Journal of Clinical Pharmacology
|
July 18, 2023
Population Pharmacokinetic Analysis of Brexpiprazole to Support its Indication and Dose Selection in Adolescents With Schizophrenia
Yanlin Wang, Xiaofeng Wang, Frank Larsen, et al.
BMC Cancer
|
July 20, 2022
ArTisaN trial protocol: a single Centre, open-label, phase II trial of the safety and efficacy of TheraSphere selective internal radiation therapy (SIRT) in the treatment of inoperable metastatic (liver) neuroendocrine neoplasia (NENs)
Rohini Sharma, Susanna Slater, Joanne Evans, et al.
Journal of Clinical Psychopharmacology
|
July 2, 2025
52-Week Open-Label Safety and Tolerability Study of Centanafadine Sustained Release in Adults With Attention-Deficit/Hyperactivity Disorder
Gregory W Mattingly, Osman Turkoglu, Denise Chang, et al.
Current Medical Research and Opinion
|
June 9, 2026
Benefits and safety of brexpiprazole in adolescents living with schizophrenia: a plain language summary
Caroline Ward, Milica Pejović Milovančević, Nanco Hefting, et al.
Journal of Clinical Psychopharmacology
|
December 30, 2025
Effects of Adjunctive Brexpiprazole in Major Depressive Disorder Analyzed by Baseline Anxiety Level: Post Hoc Analysis of a Phase 4 Study
François Therrien, Caroline Ward, Zhen Zhang, et al.
Journal of Child and Adolescent Psychopharmacology
|
February 19, 2025
Safety and Efficacy of Brexpiprazole in the Treatment of Irritability Associated with Autism Spectrum Disorder: An 8-Week, Phase 3, Randomized, Double-Blind, Placebo-Controlled Trial and 26-Week Open-Label Extension in Children and Adolescents
Caroline Ward, Ann Childress, Krista Martinko, et al.
Page
of 5